SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Balachandran Madhavan

(Last) (First) (Middle)
ONE AMGEN CENTER DRIVE

(Street)
THOUSAND OAKS CA 91320-1799

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
08/13/2012
3. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Operations
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 36,259(1)(2) D
Common Stock 28,488 I By Family Trust
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Nqso (Right to Buy) 04/28/2013 04/28/2016 Common Stock 6,000 50.44 D
Nqso (Right to Buy) 04/26/2011(3) 04/26/2020 Common Stock 24,000 58.43 D
Nqso (Right to Buy) 04/25/2013(4) 04/25/2021 Common Stock 15,750 54.69 D
Explanation of Responses:
1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 850 RSUs which fully vest on 4/28/2013; 1,750 RSUs which vest in two equal annual installments of 875 each commencing 4/26/2013; 4,500 RSUs which vest in two equal installments of 1,485 each on 4/25/2013 and 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2. These shares include 13 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3. 12,000 of these stock options are exercisable immediately and the remaining 12,000 are exercisable in two annual installments of 6,000 each commencing 4/26/2013.
4. These stock options are exercisable in three annual installments of 5,197, 5,198 and 5,355 on 4/25/2013, 4/25/2014 and 4/25/2015, respectively.
/s/ Madhavan Balachandran 08/13/2012
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Exhibit 24

Power of Attorney


		Know all men by these presents, that the undersigned hereby
constitutes and appoints each of John C. Ayres, Richard T. Benson and
Andrea A. Robinson, signing singly, the undersigneds true and lawful
attorney-in-fact to execute for and on behalf of the undersigned Forms 3,
4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of
1934, as amended, and the rules thereunder, as may be required as a result
of the undersigneds position as an officer and/or director of Amgen Inc.
(the Company).

		The undersigned hereby grants to each such attorney-in-fact
full power and authority to execute such Forms 3, 4 and 5 as fully to all
intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-facts
substitute or substitutes, shall lawfully do or cause to be done by virtue
of this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigneds
responsibilities to comply with Section 16 of the Securities Exchange Act
of 1934, as amended.

		This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to file Forms 3, 4
and 5 with respect to the undersigneds holdings of and transactions
in securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.

		IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of this 31st day of July, 2012.




						/s/   Madhavan Balachandran
						Name: Madhavan Balachandran